Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference
February 27, 2020 09:00 ET
|
Advaxis, Inc.
First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA® Partial response...
Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting
February 20, 2020 08:00 ET
|
Advaxis, Inc.
ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting Patient who previously progressed on...
Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium
February 13, 2020 08:00 ET
|
Advaxis, Inc.
Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to an estimated 11 months with...
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
February 11, 2020 08:00 ET
|
Advaxis, Inc.
PRINCETON, N.J. and MENLO PARK, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of...
Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings
January 30, 2020 09:23 ET
|
Advaxis, Inc.
PRINCETON, N.J., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering
January 21, 2020 08:30 ET
|
Advaxis, Inc.
PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
January 07, 2020 08:00 ET
|
Advaxis, Inc.
PRINCETON, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...